EUVIMEDEUVIMED entdecken
Crossref

SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma

Liqiao Chen, Liangliang Wang, Zongqi Han, Peng Qin, Guangxu Niu, Jingxia Du

The Tohoku Journal of Experimental Medicine · 2024

DOI: 10.1620/tjem.2023.j100 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Tohoku Journal of Experimental Medicine, 2024. Verfasst von Liqiao Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Basic Medical, Xingtai Medical College. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

SKI-349 is a novel sphingosine kinases (SPHK) inhibitor with anti-tumor effects. This study aimed to assess the effect of SKI-349 on cell biological behaviors, downstream pathways, and its synergistic effect with sorafenib in hepatocellular carcinoma (HCC). HCC cell lines (Huh7 and Hep3B) were treated with SKI-349 at concentrations of 1, 2, 4, or 8 μM. Then, SPHK1/2 activity, cell viability, proliferation, apoptosis, invasion, and protein expressions of phosphorylated-protein kinase B (p-AKT), AKT, phosphorylated-mammalian target of rapamycin (p-mTOR) and mTOR were detected. Combination index values of SKI-349 (0, 1, 2, 4, or 8 μM) and sorafenib (0, 2.5, 5, 10, or 20 μM) were calculated. SKI-349 decreased the relative SPHK1 and SPHK2 activity compared with blank control in a dose-dependent manner in the Huh7 and Hep3B cell lines. Meanwhile, SKI-349 reduced cell viability, 5-ethynyl-2'-deoxyuridine (EdU) positive cells, and invasive cells, while it increased apoptotic cells compared to blank control in a dose-dependent manner in Huh7 and Hep3B cell lines. Based on the western blot assay, SKI-349 decreased the ratio of p-AKT to AKT and that of p-mTOR to mTOR compared with blank control in a dose-dependent manner in the Huh7 and Hep3B cell lines. Additionally, SKI-349 combined with sorafenib declined cell viability with concentration gradient effects compared to SKI-349 sole treatment, and they had synergistic cytotoxic effects in Huh7 and Hep3B cell lines. SKI-349 suppresses SPHK1 and SPHK2 activity, cell viability, invasion, and AKT/mTOR signaling pathway, as well as exhibits a synergistic cytotoxic effect with sorafenib in HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsAntineoplastic AgentsHumansSorafenibSphingosineProto-Oncogene Proteins c-aktCell SurvivalNiacinamidePhenylurea CompoundsCell Line, TumorSignal TransductionTOR Serine-Threonine KinasesApoptosisCell Proliferation

Stichwörter der Autor:innen

AKT/mTOR signaling pathwaySKI-349hepatocellular carcinomasorafenibsphingosine kinases 1/2

Substanzen

SorafenibSphingosineProto-Oncogene Proteins c-aktNiacinamidePhenylurea CompoundsAntineoplastic AgentsTOR Serine-Threonine Kinases

Autor:innen und Institutionen

  • Department of Basic Medical, Xingtai Medical College.
  • Department of Vascular Intervention, The Second Affiliated Hospital of Xingtai Medical College.
  • Department of Pathology, Handan Central Hospital.

Zitieren

APA

Chen, L., Wang, L., Han, Z., Qin, P., Niu, G., & Du, J. (2024). SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma. The Tohoku Journal of Experimental Medicine. https://doi.org/10.1620/tjem.2023.j100

Vancouver

Chen L, Wang L, Han Z, Qin P, Niu G, Du J. SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma. The Tohoku Journal of Experimental Medicine. 2024. doi:10.1620/tjem.2023.j100

BibTeX
@article{Chen2024,
  author = {Chen, Liqiao and Wang, Liangliang and Han, Zongqi and Qin, Peng and Niu, Guangxu and Du, Jingxia},
  title = {SKI-349, a Sphingosine Kinases 1/2 Inhibitor, Suppresses Cell Viability, Invasion, and AKT/mTOR Signaling Pathway, and Shows Synergistic Cytotoxic Effects with Sorafenib in Hepatocellular Carcinoma},
  journal = {The Tohoku Journal of Experimental Medicine},
  year = {2024},
  doi = {10.1620/tjem.2023.j100}
}
Kostenlos starten →